Back to today’s briefing

Story perspectives

Eli Lilly Reports 45% Revenue Surge, Boosts 2025 Forecast

2/6/2025

42 8

Summary

Story summary

Eli Lilly achieved Q4 2024 revenue of $13.53 billion, marking a 45% year-over-year increase, fueled by Mounjaro and Zepbound.
Earnings per share (EPS) hit $5.32, surpassing market expectations.
The 2025 revenue forecast ranges from $58 billion to $61 billion, bolstered by upcoming product launches.
The company emphasizes operational efficiency, planning a $3 billion investment in manufacturing capacity.

History

Historical Context

Eli Lilly's impressive revenue growth in Q4 2024 recalls the company's strategic acquisitions, notably Icos in 2007, which enhanced its product portfolio. This historical move laid the groundwork for current successes like Mounjaro and Zepbound, showcasing the long-term impact of strategic investments in innovation.

1 of 2

Story summary

Eli Lilly achieved Q4 2024 revenue of $13.53 billion, marking a 45% year-over-year increase, fueled by Mounjaro and Zepbound.
Earnings per share (EPS) hit $5.32, surpassing market expectations.
The 2025 revenue forecast ranges from $58 billion to $61 billion, bolstered by upcoming product launches.
The company emphasizes operational efficiency, planning a $3 billion investment in manufacturing capacity.

1 / 2